Innoviva Specialty Therapeutics Products Reach Galien Final
WALTHAM, Mass., August 11, 2026 Innoviva Specialty Therapeutics (IST) announced that three of its infectious disease therapies, XACDURO® (sulbactam/durlobactam),...
AMR
Advertisement
QIAGEN Gains FDA Clearance for Bloodstream Infection Testing
Germantown, Maryland, and Venlo, Netherlands, August, 10, 2026 QIAGEN has received U.S. Food and Drug Administration (FDA) clearance for...
Saol Therapeutics Resubmits NDA for SL1009 in PDCD
ROSWELL, Ga., DUBLIN, Ireland & HAMILTON, Bermuda, July 7, 2026 Saol Therapeutics has announced the resubmission of its New...
Lakewood-Amedex Backs PASTEUR Act to Fight AMR Crisis
SARASOTA, Fla., July 7, 2026 Lakewood-Amedex Biotherapeutics has announced its support for the reintroduction of the bipartisan Pioneering Antimicrobial...
Meiji Seika Reports Positive Phase III Nacubactam Data
TOKYO, Japan, May 15, 2026 Meiji Seika Pharma Co., Ltd. announced that positive results from the global Phase III...
Advertisements
InnotiveDx Secures £1M PACE Grant for Rapid UTI Test
BATH, England — November 26, 2025. Innotive Diagnostics (InnotiveDx) has been awarded a £1 million grant from PACE, one...
Armata Pharmaceuticals Launches Advanced cGMP Phage Plant
Los Angeles, California, November 10, 2025 — Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company pioneering bacteriophage (phage) therapeutics targeting...
FDA Fast-Tracks Blacksmith’s FG-2101, a Novel Antibiotic Targeting LpxC
SAN DIEGO, California, October 13, 2025 – In a major advancement for antimicrobial innovation, Blacksmith Medicines, Inc. announced that...
Advertisement
